1. Home
  2. Directory
  3. Pennsylvania
  4. Havertown
  5. Podiatrist
  6. NPI Profile
  7. Prescriptions 1376589846

ANDREW T TEPLICA DPM
Prescription History 1376589846
Podiatrist - Foot & Ankle Surgery in Havertown, PA

NPI Status: Active since June 21, 2006

Contact Information

2800 W TOWNSHIP LINE RD
HAVERTOWN, PA
ZIP 19083
Phone: (610) 449-3344
Fax: (610) 789-6753

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ANDREW T TEPLICA DPM, an active Foot & Ankle Surgery specialist practicing in Havertown, PA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 82 documented patient claims. Among these therapy options, the most frequently utilized medication is Ciclopirox, which accounts for 40 claims alone.

Medication Index

C
G
M
No matching medications currently found on file.

Cephalexin

Generic Formulation: CephalexinSpecialty: Podiatry
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 93
PA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills28.8
Peer Average Days Supply272
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.3% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $71.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.50

State Avg Cost Per Claim

$8.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This medication will not work for viral infections (such as common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Ciclopirox

Generic Formulation: Ciclopirox OlamineSpecialty: Podiatry
Provider Metrics Summary
Total Claims 40
30-Day Fills 49.7
Days Supply 1,468
PA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills35.7
Peer Average Days Supply1,005
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,729.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$43.23

State Avg Cost Per Claim

$34.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane and pyridinone derivative that is used for the treatment of fungal infections of the skin and nails, and for treatment of VAGINAL YEAST INFECTIONS.

Therapeutic Applications

This medication is used to treat fungal infections of the fingernails and toenails. It is used as part of a treatment program that may include the removal of unattached, infected nails by a health care professional. Ciclopirox works by stopping the growth of fungus.

Gabapentin

Generic Formulation: GabapentinSpecialty: Podiatry
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 510
PA State Average Benchmarks
Peer Average Claims97.0
Peer Average 30-Day Fills141.8
Peer Average Days Supply4,057
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.5% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $219.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.90

State Avg Cost Per Claim

$21.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Mupirocin

Generic Formulation: MupirocinSpecialty: Podiatry
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 241
PA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills32.7
Peer Average Days Supply487
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.3% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $105.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.55

State Avg Cost Per Claim

$9.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.

Therapeutic Applications

Mupirocin is used to treat certain skin infections (such as impetigo). It is an antibiotic. It works by stopping the growth of certain bacteria.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ANDREW T TEPLICA DPM provides transparency into local medical care patterns within Havertown, PA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Foot & Ankle Surgery** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.